SCHEMBL659191

SCHEMBL659191

CCOC(=O)C(CC(=O)O)c1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.52
CYP2C9 P11712 4/20 0.50
CYP2C19 P33261 3/20 0.50
MEN1 O00255 2/20 0.50
CYP2D6 P10635 2/20 0.50
KMT2A Q03164 2/20 0.50
POLB P06746 3/20 0.49
GABBR2 O75899 3/20 0.49
GABBR1 Q9UBS5 3/20 0.49
LMNA P02545 2/20 0.49
CYP3A4 P08684 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
NFKB1 P19838 1/20 0.49
DRD3 P35462 1/20 0.49
BLM P54132 1/20 0.49
CYP1A2 P05177 1/20 0.49
THRB P10828 1/20 0.49
TSHR P16473 1/20 0.49
FFAR1 O14842 2/20 0.48
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1246313 0.87 L3MBTL1 (0.52) L3MBTL1CYP2C9CYP2C19POLBLMNA
SCHEMBL6390982 0.85 ESR1 (0.47) L3MBTL1CYP2C9CYP2C19MEN1CYP2D6
SCHEMBL3670529 0.85 L3MBTL1 (0.48) L3MBTL1CYP2C9CYP2C19MEN1KMT2A
SCHEMBL1545922 0.85 MMP8 (0.53) MEN1KMT2AGABBR2GABBR1TSHR
SCHEMBL4517176 0.85 L3MBTL1 (0.49) L3MBTL1CYP2C9CYP2C19MEN1KMT2A
Butane SCHEMBL5272274 0.84 L3MBTL1 (0.50) L3MBTL1CYP2C9CYP2C19POLBLMNA
SCHEMBL6321166 0.84 ALDH1A1 (0.50) L3MBTL1MEN1KMT2APOLBLMNA
SCHEMBL7632409 0.83 FFAR1 (0.52) LMNATSHRFFAR1ALDH1A1
SCHEMBL6390492 0.83 FFAR1 (0.50) L3MBTL1KMT2APOLBFFAR1TDP1
SCHEMBL27665538 0.82 L3MBTL1 (0.47) L3MBTL1CYP2C9CYP2C19POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2349999-B1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIV SAARLAND (DE) 2016-01-27 EP disclosed
US-8912186-B2 Allosteric protein kinase modulators UNIVERSITAET DES SAARLANDES (DE) 2014-12-16 US disclosed
US-20120046307-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2012-02-23 US disclosed
EP-2349999-A1 ALLOSTERIC PROTEIN KINASE MODULATORS Universität des Saarlandes (DE) 2011-08-03 EP disclosed
WO-2010043711-A1 ALLOSTERIC PROTEIN KINASE MODULATORS UNIVERSITAET DES SAARLANDES (DE) 2010-04-22 WO disclosed
EP-2177510-A1 Allosteric protein kinase modulators Universität des Saarlandes (DE) 2010-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046307-A1 ALLOSTERIC PROTEIN KINASE MODULATORS AURKC, AURKA, AURKB L3MBTL1 3302/4885CYP2C9 4696/4885CYP2C19 4532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.